The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
This study identifies 47,350 enhancers active in human neurons during differentiation and links some to genes involved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback